Adagio Therapeutics Inc Forecast, price target & analysts
Adagio Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Adagio Therapeutics Inc Classifications & Recommendation
Adagio Therapeutics Inc Price Target
| Target Price | $10.20 |
| Price | $0.82 |
| Potential |
1,140.72%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Adagio Therapeutics Inc 2027 .
The average Adagio Therapeutics Inc target price is $10.20.
This is
1,140.72%
register free of charge
$10.50
1,177.22%
register free of charge
$10.10
1,128.56%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Adagio Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Adagio Therapeutics Inc stock has an average upside potential 2027 of
1,140.72%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 53.43 | 61.27 |
| 110.52% | 14.67% | |
| EBITDA Margin | -102.58% | -253.22% |
| 85.16% | 146.84% | |
| Net Margin | -98.24% | -258.45% |
| 85.33% | 163.08% |
5 Analysts have issued a sales forecast Adagio Therapeutics Inc 2026 . The average Adagio Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Adagio Therapeutics Inc EBITDA forecast 2026. The average Adagio Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Adagio Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Adagio Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.30 | -0.54 |
| 79.02% | 80.00% | |
| P/E | negative | |
| EV/Sales | 1.34 |
5 Analysts have issued a Adagio Therapeutics Inc forecast for earnings per share. The average Adagio Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Adagio Therapeutics Inc...
Current Adagio Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BTIG |
Locked
➜
Locked
|
Locked | Sep 14 2026 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Aug 27 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jul 07 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 15 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jun 09 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jun 01 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | May 18 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BTIG:
Locked
➜
Locked
|
Sep 14 2026 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Aug 27 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jul 07 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 15 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jun 09 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jun 01 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
May 18 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
